Yu.A. Khochenkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu.A. Khochenkova has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrii A. Khochenkov
Institute of Experimental Diagnostics and Treatment of Cancer N.N. Blokhin Cancer Research Center Moscow Russia
7 shared publications - Eliso S. Solomko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Anna Sergeevna Olshanskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Ilya Tsimafeyeu
Bureau for Cancer Research - BUCARE, New York, NY 10032, USA
2 shared publications - S. A. Ashuba
FSBI N.N. Blokhin National Medical Research Center for Oncology, Moscow, Russian Federation
2 shared publications - Vsevolod Borisovich Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications
Latest Publications
- 10 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Design, Synthesis, and Evaluation of Hydrazide‐Based VEGFR‐2 Inhibitors With Antiangiogenic Potential
Angiogenesis is crucial for solid tumor growth and metastasis. Inhibiting this process, particularly via the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor‐2 (VEGFR‐2) signaling axis, is an effective anticancer strategy. We report the design and synthesis of 53 hydrazide‐based derivatives incorporating essential pharmacophoric features for VEGFR‐2 inhibition. Two synthetic routes were employed: one involving condensation of chloroacetylated amides with p‐hydroxybenzaldehyde or 6‐hydroxy‐2‐naphthaldehyde, followed by reaction with benzohydrazides; the other using substituted phenyl or naphthalene cores to probe hydrophobic interactions. Structures were confirmed by FTIR, NMR, LC–MS, and HPLC. The compounds were evaluated for cytotoxicity and VEGFR‐2 inhibitory/antiangiogenic activity via in vitro tube formation assays. SA7 emerged as a lead, showing potent cytotoxicity against various human cancer cell lines with low‐micromolar IC 50 values. VEGFR‐2 kinase inhibition confirmed its efficacy (IC 50 = 2.206 µM), comparable to sorafenib (IC 50 = 2.218 µM). SA7, SA9, and SA50 significantly inhibited capillary‐like network formation. Molecular docking revealed key interactions with VEGFR‐2 ATP‐binding residues. In vivo, SA7 suppressed HCT116 xenograft growth more effectively than irinotecan. These results position SA7 and its analogs as promising VEGFR‐2 inhibitors with strong antiproliferative and antiangiogenic potential.
- 10 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Design, Synthesis, and Evaluation of Hydrazide‐Based VEGFR‐2 Inhibitors With Antiangiogenic Potential
Angiogenesis is crucial for solid tumor growth and metastasis. Inhibiting this process, particularly via the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor‐2 (VEGFR‐2) signaling axis, is an effective anticancer strategy. We report the design and synthesis of 53 hydrazide‐based derivatives incorporating essential pharmacophoric features for VEGFR‐2 inhibition. Two synthetic routes were employed: one involving condensation of chloroacetylated amides with p‐hydroxybenzaldehyde or 6‐hydroxy‐2‐naphthaldehyde, followed by reaction with benzohydrazides; the other using substituted phenyl or naphthalene cores to probe hydrophobic interactions. Structures were confirmed by FTIR, NMR, LC–MS, and HPLC. The compounds were evaluated for cytotoxicity and VEGFR‐2 inhibitory/antiangiogenic activity via in vitro tube formation assays. SA7 emerged as a lead, showing potent cytotoxicity against various human cancer cell lines with low‐micromolar IC 50 values. VEGFR‐2 kinase inhibition confirmed its efficacy (IC 50 = 2.206 µM), comparable to sorafenib (IC 50 = 2.218 µM). SA7, SA9, and SA50 significantly inhibited capillary‐like network formation. Molecular docking revealed key interactions with VEGFR‐2 ATP‐binding residues. In vivo, SA7 suppressed HCT116 xenograft growth more effectively than irinotecan. These results position SA7 and its analogs as promising VEGFR‐2 inhibitors with strong antiproliferative and antiangiogenic potential.
- Open Access
- 21 May 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (1) , 7-11
Expression of Platelet-Derived Growth Factor Alpha and Beta Receptors in Primary Tumor Cells of Patients with Renal Cell Carcinoma
Objective: This study aimed to assess the expression of platelet-derived growth factor receptors alpha and beta (PDGFR!/") in primary tumor cells of patients with renal cell carcinoma (RCC). Methods: Platelet-derived growth factor receptors alpha and beta expression was analyzed in RCC specimens from 65 RCC patients (pT1a-T4Nany Many ) using immunohis tochemistry. Expression levels were quantified using the semi-quantitative H-score (HS) method, and correlations between PDGFR!/" expression and tumor characteris tics were evaluated. The impact of PDGFR!/" expression on patient survival was also examined. Results: Platelet-derived growth factor receptor alpha was expressed in the cytoplasm and membrane of 58.5% of primary RCC cells, with an HS of 62.9 ± 8.4, significantly higher than PDGFR" expression (44.6%; 26.6 ± 5.3; P > .05). Platelet-derived growth factor receptor alpha expression correlated with tumor grade (r = 0.471; P < .0001) and the pN+ category (r = 0.280; P = .024). Platelet-derived growth factor receptor beta expression correlated with tumor grade (r = 0.286; P = .021), venous tumor thrombosis (r = 0.263; P = .034), M+ category (r = 0.305; P = .014), and adrenal metastases (r = 0.306; P = .041). Neither PDGFR! nor PDGFR" expression levels influenced patient survival. Conclusion: Platelet-derived growth factor receptor alpha was more highly expressed in RCC cells compared to PDGFR". Overexpression of PDGFR!/" was associated with higher tumor grade and advanced RCC stages, though it did not affect patient survival. Cite this article as: Volkova M, Khochenkov D, Olshanskaya A, et!al. Expression of platelet-derived growth factor alpha and beta receptors in primary tumor cells of patients with renal cell carcinoma. Urol Res Pract. 2025;51(1):7-11.
- 21 May 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (1) , 7-11
Open AccessExpression of Platelet-Derived Growth Factor Alpha and Beta Receptors in Primary Tumor Cells of Patients with Renal Cell Carcinoma
Objective: This study aimed to assess the expression of platelet-derived growth factor receptors alpha and beta (PDGFR!/") in primary tumor cells of patients with renal cell carcinoma (RCC). Methods: Platelet-derived growth factor receptors alpha and beta expression was analyzed in RCC specimens from 65 RCC patients (pT1a-T4Nany Many ) using immunohis tochemistry. Expression levels were quantified using the semi-quantitative H-score (HS) method, and correlations between PDGFR!/" expression and tumor characteris tics were evaluated. The impact of PDGFR!/" expression on patient survival was also examined. Results: Platelet-derived growth factor receptor alpha was expressed in the cytoplasm and membrane of 58.5% of primary RCC cells, with an HS of 62.9 ± 8.4, significantly higher than PDGFR" expression (44.6%; 26.6 ± 5.3; P > .05). Platelet-derived growth factor receptor alpha expression correlated with tumor grade (r = 0.471; P < .0001) and the pN+ category (r = 0.280; P = .024). Platelet-derived growth factor receptor beta expression correlated with tumor grade (r = 0.286; P = .021), venous tumor thrombosis (r = 0.263; P = .034), M+ category (r = 0.305; P = .014), and adrenal metastases (r = 0.306; P = .041). Neither PDGFR! nor PDGFR" expression levels influenced patient survival. Conclusion: Platelet-derived growth factor receptor alpha was more highly expressed in RCC cells compared to PDGFR". Overexpression of PDGFR!/" was associated with higher tumor grade and advanced RCC stages, though it did not affect patient survival. Cite this article as: Volkova M, Khochenkov D, Olshanskaya A, et!al. Expression of platelet-derived growth factor alpha and beta receptors in primary tumor cells of patients with renal cell carcinoma. Urol Res Pract. 2025;51(1):7-11.
- Open Access
- 30 October 2022
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 21 (3) , 34-39
CD437 increases the iron uptake by metastatic melanoma cells
Background. CD437, an analog of vitamin A, is an agonist of the retinoic acid γ-receptor (RARγ). CD437 is also known to cause p53-independent DNA damage by a mechanism independent of the RAR-mediated pathway. In cancer patients, iron deficiency is constantly detect, the delivery of iron to tissues is also destroyed.Aim. To study the effect of CD437 on iron metabolism in metastatic melanoma cells, Mel Z.Materials and methods. In this study 2D cultivation of metastatic Mel Z melanoma cells, phase-contrast and fluorescence microscopy, flow cytofluorimetry were used.Results. In control cells without the addition of CD437 CD71, transferrin receptor, expressed 40 ± 4 % (p 0.05) of Mel Z cells, in the presence of CD437 CD71 expression increased to 80 ± 6 %. Next, we have studied the expression of ferritin. Iron, which is not involved in cell metabolism, is bound by ferritin. In control experiments, ferritin was expressed by 84 ± 6 % (p 0.05) of cells. When the cells grew in the presence of CD437, ferritin was expressed by all the cells (100 %, p 0.05). Such a scenario indicates that CD437 may contribute to the accumulation of free, unbound iron in the cell, which can induce ferroptosis. In control experiments without the addition of CD437, the level of membranes lipid peroxidation, an indicator of ferroptosis, was insignificant. Lipid peroxidation induced by CD437 was 55 ± 5 % (p 0.05) of the fluorescence intensity induced by erastin, positive control.Conclusion. CD437 increases the iron uptake by metastatic melanoma cells. The low level of membranes lipid peroxidation induced by CD437 does not allow it to be considered as an inducer of ferroptosis. Additional investigations are needed to find iron-binding targets alternative to ferritin.
- 30 October 2022
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 21 (3) , 34-39
Open AccessCD437 increases the iron uptake by metastatic melanoma cells
Background. CD437, an analog of vitamin A, is an agonist of the retinoic acid γ-receptor (RARγ). CD437 is also known to cause p53-independent DNA damage by a mechanism independent of the RAR-mediated pathway. In cancer patients, iron deficiency is constantly detect, the delivery of iron to tissues is also destroyed.Aim. To study the effect of CD437 on iron metabolism in metastatic melanoma cells, Mel Z.Materials and methods. In this study 2D cultivation of metastatic Mel Z melanoma cells, phase-contrast and fluorescence microscopy, flow cytofluorimetry were used.Results. In control cells without the addition of CD437 CD71, transferrin receptor, expressed 40 ± 4 % (p 0.05) of Mel Z cells, in the presence of CD437 CD71 expression increased to 80 ± 6 %. Next, we have studied the expression of ferritin. Iron, which is not involved in cell metabolism, is bound by ferritin. In control experiments, ferritin was expressed by 84 ± 6 % (p 0.05) of cells. When the cells grew in the presence of CD437, ferritin was expressed by all the cells (100 %, p 0.05). Such a scenario indicates that CD437 may contribute to the accumulation of free, unbound iron in the cell, which can induce ferroptosis. In control experiments without the addition of CD437, the level of membranes lipid peroxidation, an indicator of ferroptosis, was insignificant. Lipid peroxidation induced by CD437 was 55 ± 5 % (p 0.05) of the fluorescence intensity induced by erastin, positive control.Conclusion. CD437 increases the iron uptake by metastatic melanoma cells. The low level of membranes lipid peroxidation induced by CD437 does not allow it to be considered as an inducer of ferroptosis. Additional investigations are needed to find iron-binding targets alternative to ferritin.
- Open Access
- 25 September 2022
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 15 (3)
Biological activity of a drug, polypeptides derived from testes in a model of oxidative stress in vitro.
Introduction. Male infertility is one of the main causes of forced childlessness of couples around the world. Currently, a limited number of drugs for the treatment of male infertility are available on the market. Biologically active supplements (dietary supplements) containing L-carnitine are often used in the complex therapy. The results of determining the therapeutic activity of a new drug, a peptide complex obtained from cattle testes (PP-R-001) for the treatment of male infertility and comparing its effectiveness with L-carnitine in the models of oxidative stress induction in cell cultures are presented. Material and methods. The study was carried out on cell lines of transplanted piglet testicle (PTP) and bovine embryonic testicle (TEB). Two experimental approaches were used to induce oxidative stress (OS) in testicular cells: co-culturing cells of either PTP or TEB with cisplatin (cis-Pt) or hydrogen peroxide (H2O2). The protective effect of the PP-R-001 peptide complex was assessed by the induction of apoptosis and testicular cell death, migration activity, the number of cells with DNA double-strand breaks, the level of reactive oxygen species, mitochondrial activity of cells under OS conditions. Results. The effect of PP-R-001 significantly exceeded the effect of L-carnitine on the survival rate and decrease of apoptotic cell number of PTP and TEB under OS conditions. PP-R-001 significantly increased the migration activity of both cell lines. It was found that PP-R-001 significantly reduced the level of intracellular lesions that lead to apoptotic death of TEB and PTP cells exposed to both cis-Pt and H2O2: the drug increased the activity of mitochondria and decreased the number of DNA double-strand breaks and reactive oxygen species (ROS). Conclusion. The data obtained indicate that PP-R-001 has a multimodal effect on testicular TEB and PTP cells in the oxidative stress models, which is superior to the effect of L-carnitine widely used in male fertility supplements.
- 25 September 2022
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 15 (3)
Open AccessBiological activity of a drug, polypeptides derived from testes in a model of oxidative stress in vitro.
Introduction. Male infertility is one of the main causes of forced childlessness of couples around the world. Currently, a limited number of drugs for the treatment of male infertility are available on the market. Biologically active supplements (dietary supplements) containing L-carnitine are often used in the complex therapy. The results of determining the therapeutic activity of a new drug, a peptide complex obtained from cattle testes (PP-R-001) for the treatment of male infertility and comparing its effectiveness with L-carnitine in the models of oxidative stress induction in cell cultures are presented. Material and methods. The study was carried out on cell lines of transplanted piglet testicle (PTP) and bovine embryonic testicle (TEB). Two experimental approaches were used to induce oxidative stress (OS) in testicular cells: co-culturing cells of either PTP or TEB with cisplatin (cis-Pt) or hydrogen peroxide (H2O2). The protective effect of the PP-R-001 peptide complex was assessed by the induction of apoptosis and testicular cell death, migration activity, the number of cells with DNA double-strand breaks, the level of reactive oxygen species, mitochondrial activity of cells under OS conditions. Results. The effect of PP-R-001 significantly exceeded the effect of L-carnitine on the survival rate and decrease of apoptotic cell number of PTP and TEB under OS conditions. PP-R-001 significantly increased the migration activity of both cell lines. It was found that PP-R-001 significantly reduced the level of intracellular lesions that lead to apoptotic death of TEB and PTP cells exposed to both cis-Pt and H2O2: the drug increased the activity of mitochondria and decreased the number of DNA double-strand breaks and reactive oxygen species (ROS). Conclusion. The data obtained indicate that PP-R-001 has a multimodal effect on testicular TEB and PTP cells in the oxidative stress models, which is superior to the effect of L-carnitine widely used in male fertility supplements.
- Open Access
- 30 August 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (4) , 64-72
EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS (VEGFR-1 AND VEGFR-2) IN PRIMARY TUMOR CELLS IN PATIENTS WITH RENAL CANCER
Purpose:to study the expression of vascular endothelial growth factor (vegf-a) and its receptors (vegfr-1 and vegfr-2) in renal cell carcinoma (rcc) cells and assess the effect of the expression levels of these markers on the tumor characteristics and prognosis of patients with rcc.Material and methods. The study included 65 patients with rcc (pt1a-t4n0/+m0/+). All patients underwent radical surgery. Histological tumor tissue samples obtained during surgery were used for the study. Expression of vegfa, vegfr-1, -2 was studied by immunohistochemical staining using appropriate antibodies to receptors and growth factors.Results.Expression of vegf and vegfr-1 and vegfr-2 receptors was ound in the cytoplasm and on the membrane of primary tumor cells of patients with rcc. There was a significant direct correlation of overexpression of the markers with g 3-4 anaplasia (vegfr-1, -2) and signs of significant tumor extension, including high pt category (vegfr-1, -2), larger size of the primary tumor (vegfr-1 , -2), tumor invasion of paranephria (vegf, vegfr-1), tumor venous thrombosis (vegfr-1, -2), multiple metastases (vegf-2), metastases in the adrenal gland (vegf, vegfr-2) and liver (vegfr-1) (p0.05).Conclusion. Expression of vegfa, as well as vegfr-1 and vegfr-2 receptors, was found on the surface and in the cytoplasm of cells of the primary tumor of patients with rcc (pt1a-t4n0/+m0/+). There was a significant correlation between vegf/vegfr overexpression with a high grade (g3-4) tumor anaplasia and significant tumor extension. In univariate analysis, a significant adverse effect on specific survival of vegfr-2 overexpression was observed. In regression analysis, vegfr-2 overexpression tended to independently affect specific survival. These results show the importance of vegf/vegfr expression as biomarkers in renal cell carcinoma.
- 30 August 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (4) , 64-72
Open AccessEXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS (VEGFR-1 AND VEGFR-2) IN PRIMARY TUMOR CELLS IN PATIENTS WITH RENAL CANCER
Purpose:to study the expression of vascular endothelial growth factor (vegf-a) and its receptors (vegfr-1 and vegfr-2) in renal cell carcinoma (rcc) cells and assess the effect of the expression levels of these markers on the tumor characteristics and prognosis of patients with rcc.Material and methods. The study included 65 patients with rcc (pt1a-t4n0/+m0/+). All patients underwent radical surgery. Histological tumor tissue samples obtained during surgery were used for the study. Expression of vegfa, vegfr-1, -2 was studied by immunohistochemical staining using appropriate antibodies to receptors and growth factors.Results.Expression of vegf and vegfr-1 and vegfr-2 receptors was ound in the cytoplasm and on the membrane of primary tumor cells of patients with rcc. There was a significant direct correlation of overexpression of the markers with g 3-4 anaplasia (vegfr-1, -2) and signs of significant tumor extension, including high pt category (vegfr-1, -2), larger size of the primary tumor (vegfr-1 , -2), tumor invasion of paranephria (vegf, vegfr-1), tumor venous thrombosis (vegfr-1, -2), multiple metastases (vegf-2), metastases in the adrenal gland (vegf, vegfr-2) and liver (vegfr-1) (p0.05).Conclusion. Expression of vegfa, as well as vegfr-1 and vegfr-2 receptors, was found on the surface and in the cytoplasm of cells of the primary tumor of patients with rcc (pt1a-t4n0/+m0/+). There was a significant correlation between vegf/vegfr overexpression with a high grade (g3-4) tumor anaplasia and significant tumor extension. In univariate analysis, a significant adverse effect on specific survival of vegfr-2 overexpression was observed. In regression analysis, vegfr-2 overexpression tended to independently affect specific survival. These results show the importance of vegf/vegfr expression as biomarkers in renal cell carcinoma.
- Open Access
- 12 October 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (3) , 38-45
THE VALUE OF BASAL EXPRESSION LEVEL OF HEMOXYGENASE-1 FOR SENSITIVITY OF HUMAN MELANOMA CELLS TO OXIDATIVE STRESS IN VITRO
Introduction. The molecular basis of radio- and photodynamic therapy (PDT), the mechanism of action of a number of antitumor chemotherapy drugs is oxidative stress (OS). The enzyme hemoxygenase-I (НO-1), a molecular marker of OS, is a key participant in the system of protection and adaptation of tumor cells under stress.Objective. To find out whether the sensitivity of human melanoma tumor cells to OS depends on the basal and modulator-induced levels of НO-1 expressionMaterial and methods. Human melanoma cell lines were used in the study. The expression of mRNA НO-1 in cells was studied by real-time RT-PCR, the reactive oxygen species content in cells – by flow cytometry and the cytotoxicity of drugs – by MTT assay.Results. According to our data, human melanoma cells have different basal levels of HO-1 transcription: high (3.0–3.5 o. u.) in lines MelIL, MelP, medium (1.5 o. u.) in lines MeWo, MelZ, MelIbr and low (0.5 o. e.) – MelMe, A375).There is no direct correlation between the level of basal cell expression of HO-1 and their sensitivity to the OS inducer – Н2О2. The hemin-induced increase in HO-1 expression in cells is accompanied by doubled resistance to Н2О2. It was found that HO-1 repression in the presence of apigenin was registered in melanoma cells with different basal levels, but sensitization to Н2О2 (2–4 times) was observed only for cells with medium (MeWo) and low (A375) levels of basal HO-1 expression. It was found that the decrease in basal expression of HO-1 induced by apigenin is accompanied by an increase in the reactive oxygen species content in cells.Conclusions. The results of our research allow us to recommend natural flavon apigenin, a modulator of HO-1 expression, for inclusion in the chemotherapy and PDT regimens to increase the effectiveness of human melanoma treatment.
- 12 October 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (3) , 38-45
Open AccessTHE VALUE OF BASAL EXPRESSION LEVEL OF HEMOXYGENASE-1 FOR SENSITIVITY OF HUMAN MELANOMA CELLS TO OXIDATIVE STRESS IN VITRO
Introduction. The molecular basis of radio- and photodynamic therapy (PDT), the mechanism of action of a number of antitumor chemotherapy drugs is oxidative stress (OS). The enzyme hemoxygenase-I (НO-1), a molecular marker of OS, is a key participant in the system of protection and adaptation of tumor cells under stress.Objective. To find out whether the sensitivity of human melanoma tumor cells to OS depends on the basal and modulator-induced levels of НO-1 expressionMaterial and methods. Human melanoma cell lines were used in the study. The expression of mRNA НO-1 in cells was studied by real-time RT-PCR, the reactive oxygen species content in cells – by flow cytometry and the cytotoxicity of drugs – by MTT assay.Results. According to our data, human melanoma cells have different basal levels of HO-1 transcription: high (3.0–3.5 o. u.) in lines MelIL, MelP, medium (1.5 o. u.) in lines MeWo, MelZ, MelIbr and low (0.5 o. e.) – MelMe, A375).There is no direct correlation between the level of basal cell expression of HO-1 and their sensitivity to the OS inducer – Н2О2. The hemin-induced increase in HO-1 expression in cells is accompanied by doubled resistance to Н2О2. It was found that HO-1 repression in the presence of apigenin was registered in melanoma cells with different basal levels, but sensitization to Н2О2 (2–4 times) was observed only for cells with medium (MeWo) and low (A375) levels of basal HO-1 expression. It was found that the decrease in basal expression of HO-1 induced by apigenin is accompanied by an increase in the reactive oxygen species content in cells.Conclusions. The results of our research allow us to recommend natural flavon apigenin, a modulator of HO-1 expression, for inclusion in the chemotherapy and PDT regimens to increase the effectiveness of human melanoma treatment.
- Open Access
- 30 March 2020
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 16 (1) , 17-26-26
Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma
Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α, PDGFR-β) in paired samples of primary tumors and tumor thrombi in renal cell carcinoma (RCC).Materials and methods. Expression of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β was studied in paired surgical samples of primary tumors and tumor thrombi in 25 patients with clear cell RCC pT3a–T4N0–1M0–1 and tumor venous thrombosis by immunohistochemical assay using the appropriate Abcam/Santa Cruz Biotech antibodies from the immunohistochemical staining kit Invitrogen. Expression levels were evaluated by a semi-quantitative method (H-score). The analysis of the correlation between expression levels of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β and RCC characteristics, as well as evaluation of their influence on the outcome of RCC were performed.Results. VEGF-A, FGF-2, as well as VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β were expressed in the cytoplasm and on the membrane of the primary tumor and tumor thrombus cells in RCC patients. Tumor thrombus cells were characterized by lower expression of VEGFR-1, VEGFR-2, PDGFR-α (p 0.05 for all) and tendency to lower expression of VEGF-A (p = 0.060), FGF-2 (p = 0.046), FGFR-1 (p = 0.077) and FGFR-2 (p = 0.090) compared with primary tumor cells. RCC Furman grade correlated with the expression levels of VEGFR-1 (p = 0.035) and FGFR-1 (p = 0.022) in the primary tumor cells, tumor invasion into venous wall correlated with the expression levels of VEGFR-1 (p = 0.023) and FGFR-2 (p = 0.005) on the thrombus cells. VEGFR-2 overexpression in the primary tumor cells was associated with significant decrease of overall survival (OS) rate (p = 0.011). There was a tendency to OS deterioration in cases with overexpression of VEGFR-2 (p = 0.093) and VEGF-A (p = 0.095) in the tumor thrombus cells. One-year OS in patients with ³2 identified risk factors was 27.3 %, 2 risk factors – 87.5 % (p = 0.004).Conclusion. Tumor thrombus cells in RCC patients expressed VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β less active than the cells of the primary tumor. Overexpression of growth factors and tyrosine kinases correlated with RCC Furman grade and tumor venous wall invasion. Overexpression of VEGFR-2 in both primary tumor and thrombus cells in combination with hypoexpression of VEGF-A in the thrombus negatively influenced on OS.
- 30 March 2020
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 16 (1) , 17-26-26
Open AccessExpression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma
Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α, PDGFR-β) in paired samples of primary tumors and tumor thrombi in renal cell carcinoma (RCC).Materials and methods. Expression of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β was studied in paired surgical samples of primary tumors and tumor thrombi in 25 patients with clear cell RCC pT3a–T4N0–1M0–1 and tumor venous thrombosis by immunohistochemical assay using the appropriate Abcam/Santa Cruz Biotech antibodies from the immunohistochemical staining kit Invitrogen. Expression levels were evaluated by a semi-quantitative method (H-score). The analysis of the correlation between expression levels of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β and RCC characteristics, as well as evaluation of their influence on the outcome of RCC were performed.Results. VEGF-A, FGF-2, as well as VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β were expressed in the cytoplasm and on the membrane of the primary tumor and tumor thrombus cells in RCC patients. Tumor thrombus cells were characterized by lower expression of VEGFR-1, VEGFR-2, PDGFR-α (p 0.05 for all) and tendency to lower expression of VEGF-A (p = 0.060), FGF-2 (p = 0.046), FGFR-1 (p = 0.077) and FGFR-2 (p = 0.090) compared with primary tumor cells. RCC Furman grade correlated with the expression levels of VEGFR-1 (p = 0.035) and FGFR-1 (p = 0.022) in the primary tumor cells, tumor invasion into venous wall correlated with the expression levels of VEGFR-1 (p = 0.023) and FGFR-2 (p = 0.005) on the thrombus cells. VEGFR-2 overexpression in the primary tumor cells was associated with significant decrease of overall survival (OS) rate (p = 0.011). There was a tendency to OS deterioration in cases with overexpression of VEGFR-2 (p = 0.093) and VEGF-A (p = 0.095) in the tumor thrombus cells. One-year OS in patients with ³2 identified risk factors was 27.3 %, 2 risk factors – 87.5 % (p = 0.004).Conclusion. Tumor thrombus cells in RCC patients expressed VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β less active than the cells of the primary tumor. Overexpression of growth factors and tyrosine kinases correlated with RCC Furman grade and tumor venous wall invasion. Overexpression of VEGFR-2 in both primary tumor and thrombus cells in combination with hypoexpression of VEGF-A in the thrombus negatively influenced on OS.
- Open Access
- 15 December 2019
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 6 (4) , 69-74
New approaches in 3D modeling of in vitro growth of primary cultures of malignant gliomas
Background. The incidence of brain gliomas firmly occupies a leading position among all central nervous system tumors – 40–50 % of the cases detected, more than half of them are glioblastoma. Existing cell lines and cultivation methods do not reflect all the features of the three-dimensional (3D) organization of native glioblastoma. The use of temozolomide leads to the development of drug resistance and acute relapse, followed by a poor clinical outcome. The development of resistance is largely associated with the presence of tumor stem cells in the population and intratumoral heterogeneity. Obtaining 3D cultures from the primary material will allow us to save the stem cell pool and tumor-specific features.The study objective. Get a 3D model based on primary cell cultures, which allows you to save a heterogeneous population and the original phenotype of tumor cells.Materials and methods. We used U-87MG human glioma cells and GBM002 primary cell culture obtained from surgical material with a confirmed diagnosis of glioblastoma. Neurospheres were obtained from cell lines, the growth of which was monitored using the InCell Analyzer 6000 automatic cell analysis system. Flow cytometry was used to determine the CD133+ cell content. The expression of the receptor tyrosine kinases VEGFR1, VEGFR2 (endothelial growth factor type 1 and 2 receptors), FGFR2 (fibroblast growth factor receptor type 2) and the hypoxia marker HIF-1α (hypoxia inducible factor, 1α) in the neurospheres was evaluated using confocal microscopy.Results. GBM002 glioblastoma cells isolated from the surgical material formed neurospheres, while the number of CD133+ cells increased from 1–2 to 16–19 % compared with two-dimensional cultures. During long-term cultivation of cells with non-cytotoxic doses of temozolomide, it was found that such cells form smaller neurospheres compared to control cells. It was shown that the expression of receptor tyrosine kinases during cultivation of GBM002 glioblastoma cells in neurospheres differs from that in two-dimensional cultures. We found that in neurospheres, the expression of FGFR2 and VEGFR1, is significantly increased.Conclusion. 3D cultivation of primary cultures allows one to obtain a more heterogeneous population of tumor cells that reflects the spatial heterogeneity of cells, increase the pool of stem cells and recreate hypoxia conditions inside the brain micro-tumors.
- 15 December 2019
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 6 (4) , 69-74
Open AccessNew approaches in 3D modeling of in vitro growth of primary cultures of malignant gliomas
Background. The incidence of brain gliomas firmly occupies a leading position among all central nervous system tumors – 40–50 % of the cases detected, more than half of them are glioblastoma. Existing cell lines and cultivation methods do not reflect all the features of the three-dimensional (3D) organization of native glioblastoma. The use of temozolomide leads to the development of drug resistance and acute relapse, followed by a poor clinical outcome. The development of resistance is largely associated with the presence of tumor stem cells in the population and intratumoral heterogeneity. Obtaining 3D cultures from the primary material will allow us to save the stem cell pool and tumor-specific features.The study objective. Get a 3D model based on primary cell cultures, which allows you to save a heterogeneous population and the original phenotype of tumor cells.Materials and methods. We used U-87MG human glioma cells and GBM002 primary cell culture obtained from surgical material with a confirmed diagnosis of glioblastoma. Neurospheres were obtained from cell lines, the growth of which was monitored using the InCell Analyzer 6000 automatic cell analysis system. Flow cytometry was used to determine the CD133+ cell content. The expression of the receptor tyrosine kinases VEGFR1, VEGFR2 (endothelial growth factor type 1 and 2 receptors), FGFR2 (fibroblast growth factor receptor type 2) and the hypoxia marker HIF-1α (hypoxia inducible factor, 1α) in the neurospheres was evaluated using confocal microscopy.Results. GBM002 glioblastoma cells isolated from the surgical material formed neurospheres, while the number of CD133+ cells increased from 1–2 to 16–19 % compared with two-dimensional cultures. During long-term cultivation of cells with non-cytotoxic doses of temozolomide, it was found that such cells form smaller neurospheres compared to control cells. It was shown that the expression of receptor tyrosine kinases during cultivation of GBM002 glioblastoma cells in neurospheres differs from that in two-dimensional cultures. We found that in neurospheres, the expression of FGFR2 and VEGFR1, is significantly increased.Conclusion. 3D cultivation of primary cultures allows one to obtain a more heterogeneous population of tumor cells that reflects the spatial heterogeneity of cells, increase the pool of stem cells and recreate hypoxia conditions inside the brain micro-tumors.